Public Profile

Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2007, the company has established itself as a leader in developing innovative injectable products, particularly in the areas of oncology and critical care. With a focus on improving patient outcomes, Eagle Pharmaceuticals offers unique formulations that enhance the delivery and efficacy of established therapies. The company has achieved significant milestones, including the successful launch of its flagship product, Ryanodex, which is designed for the treatment of malignant hyperthermia. Eagle's commitment to quality and innovation has positioned it favourably in a competitive market, earning recognition for its contributions to patient care and drug accessibility. With operations extending across major regions in the US, Eagle Pharmaceuticals continues to drive advancements in the biopharmaceutical landscape.

DitchCarbon Score

How does Eagle Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

13

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

2

Industry Benchmark

Eagle Pharmaceuticals, Inc.'s score of 13 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.

59%

Eagle Pharmaceuticals, Inc.'s reported carbon emissions

Eagle Pharmaceuticals, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is challenging to assess their climate impact or sustainability efforts. However, the pharmaceutical industry is increasingly focusing on reducing carbon footprints and enhancing sustainability practices. Eagle Pharmaceuticals may be expected to align with industry standards and pursue climate commitments in the future.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Eagle Pharmaceuticals, Inc.'s primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Eagle Pharmaceuticals, Inc. is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Eagle Pharmaceuticals, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Similar Organizations

Sandoz

CH
Medical, precision and optical instruments, watches and clocks (33)
Updated 1 day ago

Hospira

US
Medical, precision and optical instruments, watches and clocks (33)
Updated 22 days ago

Hikma Pharmaceuticals

GB
Health and social work services (85)
Updated 5 days ago

Sandoz Inc.

US
Chemicals nec
Updated 19 days ago
DitchCarbon Score

Heron Therapeutics, Inc.

US
Health and social work services (85)
Updated 5 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers